Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vector-based gene therapy is currently the only in vivo gene therapy approved in the US and Europe. The recent tragic death of three children in a clinical trial to treat X-Linked Myotubular Myopathy by delivering myotubularin with an AAV8 vector notwithstanding, AAV remains a highly promising therapeutic gene delivery platform. But the successful use of AAV vectors to treat an increasing number of diseases also makes establishing protocols to determine therapeutically relevant titers of pre-existing anti-AAV antibodies and approaches to deplete those antibodies more urgent than ever. In this mini review, I will briefly discuss (i) our knowledge regarding the prevalence of anti-AAV antibodies, (ii) the challenges to measure those antibodies by methods that are most predictive of their influence on therapeutic efficacy of AAV gene transfer, and (iii) approaches to overcome the formidable hurdle that anti-AAV antibodies pose to the successful clinical use of AAV gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694 · cited 1×
“For instance, for their hemophilia A trial (NCT02576795) (13), Biomarin only enrolled patients that had no neutralizing antibodies against AAV5.”
BackgroundProtein length in eukaryotic and prokaryotic proteomes
Brocchieri, L. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki615 · Cited by 414
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
Self-citationOnasemnogene Abeparvovec: First Global Approval
Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01162-5 · Cited by 337
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336
Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301 · cited 1×
“Uniqure, on the other hand, used a GFP based assay for their hemophilia B trial (NCT02396342) (15) without reporting the MOI.”
BackgroundScallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · cited 2×
““Traditional” plasmapheresis, which removes all immunoglobulins, has shown some promise in depleting most NAbs from patient sera, albeit only in patients with low NAb titers (25).”
BackgroundMoving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
Wilson, J. M., & Flotte, T. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.182 · Cited by 203 · cited 1×
“This trial is currently on hold, and the cause of the deaths of the three children is under active investigation [Wilson and Flotte (6) and references cited therein].”
Background
Cited by
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes
West, C., Federspiel, J. D., Rogers, K., Khatri, A., Rao-Dayton, S., Ocana, M. F., Lim, S., D'Antona, A. M., Casinghino, S., & Somanathan, S. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.018 · Cited by 39
“Positive serostatus is often an exclusion criterion in AAV clinical trials that require intravenous vector infusion.(21) The basis for seropositive patient exclusion was based on preclinical studies and clinical trials demonstrating inefficient gene transfer following systemic vector administration to antibody-positiv…”
Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer’s disease
Li, H., Cao, Y., Ye, J., Yang, Z., Chen, Q., Liu, X., Zhang, B., Qiao, J., Tang, Q., Yang, H., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.143152 · Cited by 32
“Additionally, gene therapy remains some barriers to its use, after repeat injection, the virus will be cleared by specific neutralization antibody [5].”
Leray, A., Lalys, P.-A., Varin, J., Bouzelha, M., Bourdon, A., Alvarez-Dorta, D., Pavageau, K., Depienne, S., Marchand, M., Mellet, A., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116148 · Cited by 17
Metadata
- Authors
- Weber, T.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-17
- Volume
- 12
- Pages
- 658399-658399
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3139128149
- Cited by
- 157
- References
- 17
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions. https://app.cochat.ai/papers/10.3389/fimmu.2021.658399
- The paper
- Weber, T. (2021). Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.658399
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.